{"gene":"ELOVL1","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2010,"finding":"ELOVL1 exhibits high enzymatic activity toward saturated and monounsaturated C20- and C22-CoAs, catalyzing their elongation to C24-CoA, and is essential for the production of C24 sphingolipids; its activity is co-regulated with ceramide synthase CERS2 to coordinate C24-CoA production with utilization; knockdown of ELOVL1 reduces LYN kinase activity, confirming C24-sphingolipid importance in membrane microdomain function.","method":"In vitro elongase activity assay with all seven ELOVL family members; siRNA knockdown; LYN kinase activity measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro substrate specificity assay across all ELOVLs with functional knockdown validation, replicated in multiple contexts","pmids":["20937905"],"is_preprint":false},{"year":2010,"finding":"ELOVL1 is the single elongase responsible for synthesizing both saturated VLCFA (C26:0) and monounsaturated VLCFA (C26:1) from C22 substrates; ELOVL1 knockdown reduces C22:0-to-C26:0 elongation and lowers C26:0 levels in X-ALD fibroblasts, demonstrating that elevated C26:0 in X-ALD results from increased substrate availability (cytosolic VLCFA-CoA) rather than increased ELOVL1 expression.","method":"Stable isotope elongation assay; siRNA knockdown of ELOVL1 in X-ALD fibroblasts; GC-MS fatty acid profiling","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal biochemical methods in patient-derived cells with functional rescue","pmids":["20166112"],"is_preprint":false},{"year":2013,"finding":"Elovl1 knockout mice die shortly after birth due to epidermal barrier defects; in the epidermis, loss of Elovl1 reduces ceramides with ≥C26 fatty acids and increases ceramides with ≤C24 fatty acids, and reduces C24 sphingomyelin; CerS2 and CerS3, expressed in epidermal-layer-specific manner, regulate Elovl1 to produce acyl-CoAs of different chain lengths, establishing Elovl1 as a key determinant of epidermal ceramide chain length.","method":"Elovl1 knockout mouse generation; lipidomics of stratum corneum; ultrastructural analysis of lipid lamellae; immunofluorescence for CerS2/CerS3","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with defined lipid phenotype plus molecular characterization of CerS2/CerS3 interaction","pmids":["23689133"],"is_preprint":false},{"year":2014,"finding":"Oleic and erucic acids (components of Lorenzo's oil) inhibit ELOVL1 in a mixed (non-competitive) inhibition kinetics manner; the 4:1 mixture (Lorenzo's oil composition) shows the most potent inhibitory activity and reduces saturated VLCFA-sphingomyelin levels in cells, suggesting ELOVL1 inhibition underlies Lorenzo's oil mechanism of action.","method":"ELOVL1 activity assay with kinetic analysis; cellular sphingomyelin profiling by LC-MS/MS","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic kinetics with cellular validation","pmids":["24489110"],"is_preprint":false},{"year":2014,"finding":"CoA esters of bezafibrate and gemfibrozil specifically inhibit ELOVL1 enzymatic activity; kinetic characterization using microsomal fractions from ELOVL1-overexpressing HEK293 cells established that fibrates act as inhibitors of ELOVL1-mediated chain elongation.","method":"Microsomal elongation assay from ELOVL1-overexpressing HEK293 cells; inhibition kinetics with fibrate CoA esters; X-ALD fibroblast elongation assay","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzyme kinetics with defined inhibitor mechanism","pmids":["25499606"],"is_preprint":false},{"year":2018,"finding":"A dominant de novo ELOVL1 mutation (p.S165F) abrogates ELOVL1 enzymatic activity, reduces ≥C24 ceramides and sphingomyelins in patient fibroblasts, and causes ichthyosis, hypomyelination, spastic paraplegia, and optic atrophy; loading fibroblasts with C22:0-VLCFAs increased C24:0-ceramides and sphingomyelins, and competitive inhibition between saturated and monounsaturated VLCFAs for ceramide and sphingomyelin synthesis was identified.","method":"Stable isotope-labelled [13C]malonyl-CoA elongation assay; LC-MS/MS ceramide/sphingomyelin quantification; patient fibroblast studies; VLCFA loading experiments","journal":"Journal of medical genetics","confidence":"High","confidence_rationale":"Tier 1–2 — direct enzymatic assay with patient mutation, multiple orthogonal methods, confirmed by independent lab (PMID 29496980)","pmids":["30487246","29496980"],"is_preprint":false},{"year":2018,"finding":"Elovl1 gene disruption in mice shortens acyl chain lengths in cholesteryl esters and wax esters in meibum lipids, causing dry eye phenotypes (increased eye-blink frequency, elevated water evaporation from ocular surface); aged Elovl1 mutant mice develop corneal opacity, establishing ELOVL1 as the primary elongase for saturated VLC meibum fatty acids and as essential for tear film lipid barrier function.","method":"Tissue-specific Elovl1 knockout mice; meibum lipid profiling; eye-blink frequency measurement; corneal phenotype analysis","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined lipid and functional phenotype, replicated in follow-up study (PMID 41539567)","pmids":["29401594"],"is_preprint":false},{"year":2019,"finding":"Elovl1 mutant mice show markedly shortened acyl chain lengths of sphingolipids (galactosylceramides, sulfatides, sphingomyelins, ceramides) in the brain, reduced galactosylceramide levels, modest hypomyelination especially in large-diameter axons, and behavioral deficits including poorer motor coordination and reduced acoustic startle response.","method":"Elovl1 mutant mouse analysis; brain lipidomics; electron microscopy of corpus callosum; behavioral testing","journal":"FASEB bioAdvances","confidence":"High","confidence_rationale":"Tier 2 — genetic model with lipidomic and ultrastructural characterization plus functional behavioral readout","pmids":["32123819"],"is_preprint":false},{"year":2002,"finding":"Elovl1 encodes a ubiquitously expressed microsomal enzyme involved in very long-chain fatty acid and sphingolipid synthesis; the mouse Elovl1 gene consists of eight exons spanning 5.4 kb and is arranged in a tail-to-tail array with the cell cycle gene p55Cdc, with both genes co-expressed during proliferation-differentiation transitions.","method":"Genomic cloning; DNA sequencing; Northern blot mRNA analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — genomic characterization and expression analysis, single study","pmids":["11891222"],"is_preprint":false},{"year":2016,"finding":"In zebrafish, Elovl1 knockdown increases long-chain fatty acids (C14–C20) and causes lipid droplet accumulation in the swim bladder; Elovl1a and Elovl1b are required for swim bladder inflation and gene expression in swim bladder development, while Elovl1b is additionally required for kidney development and renal clearance.","method":"Morpholino knockdown of elovl1a/b in zebrafish; Oil-Red-O lipid staining; gene expression analysis; renal clearance assay","journal":"Organogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockdown with lipid quantification and organogenesis phenotype, zebrafish ortholog","pmids":["27078170"],"is_preprint":false},{"year":2022,"finding":"A homozygous splice site mutation in ELOVL1 (c.376-2A>G) causes exon skipping, leading to loss of ELOVL1 function with autosomal recessive inheritance; LC-MS/MS analysis of patient stratum corneum showed significant shortening of fatty acid moieties and severe reduction in acylceramide levels.","method":"Whole exome sequencing; RNA splicing analysis; LC-MS/MS ceramide profiling of stratum corneum","journal":"Brain & development","confidence":"Medium","confidence_rationale":"Tier 2 — molecular characterization of splice variant with biochemical confirmation in patient tissue","pmids":["35379526"],"is_preprint":false},{"year":2025,"finding":"Elovl1 inactivation in CD8+ T cells leads to accumulation of saturated long-chain fatty acids, which destabilizes INSIG1, activates SREBP2, increases plasma membrane cholesterol, and strengthens T cell receptor signaling; Elovl1-deficient T cells also show increased mitochondrial fitness and fatty acid oxidation.","method":"CRISPR/Cas9 metabolic screen; single-cell RNA sequencing; adoptive T cell transfer in vivo; INSIG1/SREBP2 pathway analysis; metabolic profiling","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 — genome-wide CRISPR screen with mechanistic pathway validation (INSIG1-SREBP2), multiple orthogonal methods","pmids":["40065102"],"is_preprint":false},{"year":2024,"finding":"Simvastatin downregulates ELOVL1 expression in astrocytes by inhibiting mTOR signaling after traumatic brain injury; overexpression of ELOVL1 in astrocytes partially attenuates the neuroprotective benefits of simvastatin, establishing that astrocytic ELOVL1 mediates VLCFA-dependent neurotoxicity downstream of mTOR.","method":"In vivo cryogenic TBI mouse model; AAV-mediated astrocytic ELOVL1 overexpression; mTOR pathway inhibition; saturated VLCFA quantification in cortex","journal":"Brain research bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — genetic overexpression with pharmacological intervention and defined pathway placement","pmids":["39243948"],"is_preprint":false},{"year":2025,"finding":"CRISPRi screening identified ELOVL1 as a key mediator of 1-deoxy-sphingolipid (1-deoxySL) toxicity; pharmacological inhibition of ELOVL1 alleviated cellular, mitochondrial, and neuronal toxicity induced by 1-deoxySLs; mechanistic studies showed that 1-deoxyDHceramide conjugated to nervonic acid (m18:0/24:1, a product requiring ELOVL1 activity) is the principal toxic species, inducing apoptosis through mitochondrial permeability transition pore formation.","method":"CRISPRi screen; genetic knockdown; cytotoxicity assays; stable isotope-resolved lipidomics via LC-MS/MS; mPTP inhibition with cyclosporin A; BAX inhibition","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR screen with mechanistic validation, preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.05.13.653734"],"is_preprint":true}],"current_model":"ELOVL1 is a microsomal fatty acid elongase that catalyzes the rate-limiting condensation step in very long-chain fatty acid (VLCFA) synthesis, acting preferentially on saturated and monounsaturated C20–C22-CoA substrates to produce C24–C26 VLCFAs; these products are essential for C24-sphingolipid and acylceramide synthesis (coordinated with CERS2/CERS3), epidermal permeability barrier formation, tear film lipid composition, and myelin sphingolipid integrity, while in CD8+ T cells ELOVL1 activity controls membrane cholesterol homeostasis via an INSIG1-SREBP2 axis, and its inhibition is pursued therapeutically in X-linked adrenoleukodystrophy to reduce pathological C26:0 accumulation."},"narrative":{"teleology":[{"year":2002,"claim":"Initial genomic characterization established that Elovl1 encodes a ubiquitously expressed microsomal enzyme involved in VLCFA and sphingolipid synthesis, providing the gene identity needed for subsequent functional studies.","evidence":"Genomic cloning, sequencing, and Northern blot analysis in mouse","pmids":["11891222"],"confidence":"Medium","gaps":["Single descriptive study without enzymatic characterization","No substrate specificity determined","No loss-of-function data"]},{"year":2010,"claim":"Biochemical comparison of all seven ELOVL family members revealed that ELOVL1 is the primary elongase for saturated and monounsaturated C20–C22-CoAs to C24–C26, resolving which elongase produces the bulk of VLCFA for sphingolipid synthesis and establishing that elevated C26:0 in X-ALD reflects increased substrate availability rather than ELOVL1 overexpression.","evidence":"In vitro elongase activity assays across all ELOVLs; stable isotope elongation assays and siRNA knockdown in X-ALD patient fibroblasts; GC-MS profiling","pmids":["20937905","20166112"],"confidence":"High","gaps":["No in vivo genetic confirmation yet in mammals","Regulation of ELOVL1 expression and activity incompletely defined","Precise mechanism of ELOVL1–CERS2 co-regulation unknown"]},{"year":2013,"claim":"Genetic knockout in mice demonstrated that Elovl1 is non-redundant and essential for epidermal barrier function: loss of Elovl1 shortened ceramide acyl chains below C26, disrupted lipid lamellae, and caused neonatal lethality, establishing the physiological requirement for ELOVL1 in skin.","evidence":"Elovl1 knockout mice; stratum corneum lipidomics; ultrastructural analysis; CerS2/CerS3 immunofluorescence","pmids":["23689133"],"confidence":"High","gaps":["Contribution to non-epidermal tissues not yet assessed in this model","Whether CerS3 can partially compensate in specific skin layers unclear","No human genetic confirmation at this time"]},{"year":2014,"claim":"Pharmacological studies showed that Lorenzo's oil fatty acids and fibrate-CoA esters inhibit ELOVL1 via mixed inhibition kinetics, identifying ELOVL1 as a druggable target for reducing pathological VLCFA accumulation.","evidence":"Microsomal ELOVL1 activity assays with kinetic analysis; LC-MS/MS cellular sphingomyelin profiling; inhibition studies in X-ALD fibroblasts","pmids":["24489110","25499606"],"confidence":"High","gaps":["In vivo efficacy of ELOVL1 inhibition for X-ALD not demonstrated","No selective small-molecule ELOVL1 inhibitor developed","Structural basis for inhibitor binding unknown"]},{"year":2018,"claim":"A dominant de novo ELOVL1 mutation (p.S165F) was shown to abolish enzymatic activity and cause ichthyosis, hypomyelination, spastic paraplegia, and optic atrophy in humans, while tissue-specific knockout in mice revealed ELOVL1's essential role in meibum VLCFA synthesis and tear film integrity, together extending the phenotypic spectrum from skin to brain and eye.","evidence":"Patient fibroblast isotope-labelled elongation assays and LC-MS/MS; tissue-specific Elovl1 knockout mice with meibum lipidomics and ocular phenotyping","pmids":["30487246","29496980","29401594"],"confidence":"High","gaps":["Genotype–phenotype correlations across multiple mutations not established","Whether dominant-negative vs. haploinsufficiency mechanism applies unclear","No therapeutic rescue in human disease attempted"]},{"year":2019,"claim":"Brain-focused analysis of Elovl1 mutant mice revealed shortened sphingolipid acyl chains, reduced galactosylceramide, modest hypomyelination of large-diameter axons, and behavioral deficits, establishing ELOVL1's specific contribution to CNS myelin lipid composition.","evidence":"Brain lipidomics; corpus callosum electron microscopy; motor coordination and acoustic startle behavioral testing in Elovl1 mutant mice","pmids":["32123819"],"confidence":"High","gaps":["Degree to which other elongases compensate in brain not quantified","Impact on peripheral nervous system myelin not assessed","Mechanism linking shortened acyl chains to hypomyelination not defined"]},{"year":2022,"claim":"Identification of a homozygous splice site mutation confirmed autosomal recessive ELOVL1 deficiency as a human disease with severe acylceramide loss in stratum corneum, complementing the earlier dominant mutation and broadening the genetic landscape.","evidence":"Whole exome sequencing; RNA splicing analysis; LC-MS/MS ceramide profiling of patient stratum corneum","pmids":["35379526"],"confidence":"Medium","gaps":["Single family reported","Functional rescue not performed","CNS phenotype characterization limited"]},{"year":2024,"claim":"Simvastatin was shown to downregulate ELOVL1 expression in astrocytes via mTOR inhibition, and astrocytic ELOVL1 overexpression partially reversed neuroprotection, placing ELOVL1 as a mediator of VLCFA-dependent neurotoxicity downstream of mTOR signaling after traumatic brain injury.","evidence":"Cryogenic TBI mouse model; AAV-mediated astrocytic ELOVL1 overexpression; mTOR pathway analysis; cortical VLCFA quantification","pmids":["39243948"],"confidence":"Medium","gaps":["Causal link between specific VLCFA species and neurotoxicity not fully resolved","Single pharmacological agent used to define pathway","Not confirmed in human astrocytes"]},{"year":2025,"claim":"A CRISPR metabolic screen in CD8+ T cells uncovered a non-canonical role for ELOVL1: its loss shifts fatty acid composition to destabilize INSIG1, activate SREBP2-mediated cholesterol synthesis, increase plasma membrane cholesterol, and amplify TCR signaling, enhancing antitumor T cell function in vivo.","evidence":"Genome-wide CRISPR/Cas9 screen; single-cell RNA-seq; adoptive T cell transfer; INSIG1/SREBP2 pathway analysis; metabolic profiling","pmids":["40065102"],"confidence":"High","gaps":["Specific ELOVL1 substrate(s) responsible for INSIG1 destabilization not identified at lipid species level","Impact on other immune cell types unknown","Therapeutic window for T cell-directed ELOVL1 inhibition not established"]},{"year":null,"claim":"Key unresolved questions include the structural basis for ELOVL1 substrate selectivity and inhibitor binding, the development of selective ELOVL1 inhibitors suitable for clinical use, the full genotype–phenotype spectrum of ELOVL1 deficiency in humans, and the molecular mechanism linking shortened acyl-chain sphingolipids to hypomyelination.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of ELOVL1","No selective small-molecule inhibitor advanced to preclinical studies","Mechanism by which C24-sphingolipid loss causes myelin instability not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,3,4,5]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,8]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,3,5,6,7]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11]}],"complexes":[],"partners":["CERS2","CERS3","INSIG1"],"other_free_text":[]},"mechanistic_narrative":"ELOVL1 is a ubiquitously expressed microsomal fatty acid elongase that catalyzes the rate-limiting condensation step in very long-chain fatty acid (VLCFA) synthesis, preferentially elongating saturated and monounsaturated C20–C22-CoA substrates to C24–C26 products that serve as precursors for sphingolipids, acylceramides, and meibum wax esters [PMID:20937905, PMID:20166112]. Its activity is coordinated with ceramide synthases CERS2 and CERS3 to match acyl-CoA production with utilization, and is essential for epidermal permeability barrier formation, tear film lipid integrity, and myelin sphingolipid composition, as demonstrated by neonatal lethality from barrier failure in knockout mice and hypomyelination with behavioral deficits in mutant mice [PMID:23689133, PMID:29401594, PMID:32123819]. Dominant (p.S165F) and recessive loss-of-function mutations in human ELOVL1 cause ichthyosis, hypomyelination, and spastic paraplegia, with patient fibroblasts and stratum corneum showing severe reductions in ≥C24 ceramides and sphingomyelins [PMID:30487246, PMID:35379526]. In CD8+ T cells, ELOVL1 inactivation shifts fatty acid pools to destabilize INSIG1, activate SREBP2-dependent cholesterol biosynthesis, increase membrane cholesterol, and enhance T cell receptor signaling and antitumor function [PMID:40065102]."},"prefetch_data":{"uniprot":{"accession":"Q9BW60","full_name":"Very long chain fatty acid elongase 1","aliases":["3-keto acyl-CoA synthase ELOVL1","ELOVL fatty acid elongase 1","ELOVL FA elongase 1","Elongation of very long chain fatty acids protein 1","Very long chain 3-ketoacyl-CoA synthase 1","Very long chain 3-oxoacyl-CoA synthase 1"],"length_aa":279,"mass_kda":32.7,"function":"Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle (PubMed:29496980, PubMed:30487246). This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated and monounsaturated acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis (PubMed:20937905). Indirectly inhibits RPE65 via production of VLCFAs","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q9BW60/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ELOVL1","classification":"Not Classified","n_dependent_lines":142,"n_total_lines":1208,"dependency_fraction":0.11754966887417219},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000066322","cell_line_id":"CID000315","localizations":[{"compartment":"vesicles","grade":3}],"interactors":[{"gene":"CANX","stoichiometry":0.2},{"gene":"RAB11B","stoichiometry":0.2},{"gene":"RAE1","stoichiometry":0.2},{"gene":"DCTN2","stoichiometry":0.2},{"gene":"UBE3B","stoichiometry":0.2},{"gene":"ANP32A","stoichiometry":0.2},{"gene":"VDAC1","stoichiometry":0.2},{"gene":"TAGLN2","stoichiometry":0.2},{"gene":"LDHA","stoichiometry":0.2},{"gene":"DHFR","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000315","total_profiled":1310},"omim":[{"mim_id":"618527","title":"ICHTHYOTIC KERATODERMA, SPASTICITY, HYPOMYELINATION, AND DYSMORPHIC FACIAL FEATURES; IKSHD","url":"https://www.omim.org/entry/618527"},{"mim_id":"614451","title":"ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 7; ELOVL7","url":"https://www.omim.org/entry/614451"},{"mim_id":"611815","title":"ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 3; ELOVL3","url":"https://www.omim.org/entry/611815"},{"mim_id":"611814","title":"ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 2; ELOVL2","url":"https://www.omim.org/entry/611814"},{"mim_id":"611813","title":"ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 1; ELOVL1","url":"https://www.omim.org/entry/611813"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Endoplasmic reticulum","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":357.2}],"url":"https://www.proteinatlas.org/search/ELOVL1"},"hgnc":{"alias_symbol":["Ssc1"],"prev_symbol":[]},"alphafold":{"accession":"Q9BW60","domains":[{"cath_id":"-","chopping":"27-262","consensus_level":"high","plddt":93.6972,"start":27,"end":262}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BW60","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BW60-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BW60-F1-predicted_aligned_error_v6.png","plddt_mean":89.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ELOVL1","jax_strain_url":"https://www.jax.org/strain/search?query=ELOVL1"},"sequence":{"accession":"Q9BW60","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BW60.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BW60/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BW60"}},"corpus_meta":[{"pmid":"20937905","id":"PMC_20937905","title":"ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20937905","citation_count":296,"is_preprint":false},{"pmid":"2674677","id":"PMC_2674677","title":"SSC1, an essential member of the yeast HSP70 multigene family, encodes a mitochondrial protein.","date":"1989","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2674677","citation_count":213,"is_preprint":false},{"pmid":"3035571","id":"PMC_3035571","title":"SSC1, a member of the 70-kDa heat shock protein multigene family of Saccharomyces cerevisiae, is essential for growth.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3035571","citation_count":168,"is_preprint":false},{"pmid":"23689133","id":"PMC_23689133","title":"Impaired epidermal permeability barrier in mice lacking elovl1, the gene responsible for very-long-chain fatty acid production.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23689133","citation_count":144,"is_preprint":false},{"pmid":"20166112","id":"PMC_20166112","title":"The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy.","date":"2010","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20166112","citation_count":136,"is_preprint":false},{"pmid":"11096111","id":"PMC_11096111","title":"Mitochondrial Hsp70 Ssc1: role in protein folding.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11096111","citation_count":89,"is_preprint":false},{"pmid":"9048947","id":"PMC_9048947","title":"Mge1 functions as a nucleotide release factor for Ssc1, a mitochondrial Hsp70 of Saccharomyces cerevisiae.","date":"1997","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9048947","citation_count":81,"is_preprint":false},{"pmid":"10779357","id":"PMC_10779357","title":"Role of the mitochondrial Hsp70s, Ssc1 and Ssq1, in the maturation of Yfh1.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10779357","citation_count":74,"is_preprint":false},{"pmid":"21068384","id":"PMC_21068384","title":"Cox25 teams up with Mss51, Ssc1, and Cox14 to regulate mitochondrial cytochrome c oxidase subunit 1 expression and assembly in Saccharomyces cerevisiae.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21068384","citation_count":68,"is_preprint":false},{"pmid":"30487246","id":"PMC_30487246","title":"De novo mutation in ELOVL1 causes ichthyosis, acanthosis nigricans, hypomyelination, spastic paraplegia, high frequency deafness and optic atrophy.","date":"2018","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30487246","citation_count":59,"is_preprint":false},{"pmid":"29401594","id":"PMC_29401594","title":"Very long-chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29401594","citation_count":57,"is_preprint":false},{"pmid":"29496980","id":"PMC_29496980","title":"Dominant ELOVL1 mutation causes neurological disorder with ichthyotic keratoderma, spasticity, hypomyelination and dysmorphic features.","date":"2018","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29496980","citation_count":48,"is_preprint":false},{"pmid":"24489110","id":"PMC_24489110","title":"Lorenzo's oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24489110","citation_count":47,"is_preprint":false},{"pmid":"11601843","id":"PMC_11601843","title":"The two mitochondrial heat shock proteins 70, Ssc1 and Ssq1, compete for the cochaperone Mge1.","date":"2001","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11601843","citation_count":33,"is_preprint":false},{"pmid":"25499606","id":"PMC_25499606","title":"Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25499606","citation_count":32,"is_preprint":false},{"pmid":"32123819","id":"PMC_32123819","title":"Reduced chain length in myelin sphingolipids and poorer motor coordination in mice deficient in the fatty acid elongase Elovl1.","date":"2019","source":"FASEB bioAdvances","url":"https://pubmed.ncbi.nlm.nih.gov/32123819","citation_count":25,"is_preprint":false},{"pmid":"27078170","id":"PMC_27078170","title":"The fatty acid chain elongase, Elovl1, is required for kidney and swim bladder development during zebrafish embryogenesis.","date":"2016","source":"Organogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27078170","citation_count":25,"is_preprint":false},{"pmid":"35379526","id":"PMC_35379526","title":"Hypomyelinating spastic dyskinesia and ichthyosis caused by a homozygous splice site mutation leading to exon skipping in ELOVL1.","date":"2022","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/35379526","citation_count":22,"is_preprint":false},{"pmid":"21474445","id":"PMC_21474445","title":"Primary sequence that determines the functional overlap between mitochondrial heat shock protein 70 Ssc1 and Ssc3 of Saccharomyces cerevisiae.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21474445","citation_count":13,"is_preprint":false},{"pmid":"34748351","id":"PMC_34748351","title":"Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34748351","citation_count":10,"is_preprint":false},{"pmid":"34871500","id":"PMC_34871500","title":"Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34871500","citation_count":10,"is_preprint":false},{"pmid":"40065102","id":"PMC_40065102","title":"A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8+ T cell fitness in solid tumours.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40065102","citation_count":9,"is_preprint":false},{"pmid":"10196216","id":"PMC_10196216","title":"Interaction between the nucleotide exchange factor Mge1 and the mitochondrial Hsp70 Ssc1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10196216","citation_count":9,"is_preprint":false},{"pmid":"16167980","id":"PMC_16167980","title":"Mapping of 443 porcine EST improves the comparative maps for SSC1 and SSC7 with the human genome.","date":"2005","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16167980","citation_count":9,"is_preprint":false},{"pmid":"27081361","id":"PMC_27081361","title":"Development of Cotton leaf curl virus resistant transgenic cotton using antisense ßC1 gene.","date":"2014","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27081361","citation_count":7,"is_preprint":false},{"pmid":"11891222","id":"PMC_11891222","title":"Elovl1 and p55Cdc genes are localized in a tail-to-tail array and are co-expressed in proliferating cells.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11891222","citation_count":7,"is_preprint":false},{"pmid":"39144963","id":"PMC_39144963","title":"ELOVL1 is upregulated and promotes tumor growth in hepatocellular carcinoma through regulating PI3K-AKT-mTOR signaling.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39144963","citation_count":4,"is_preprint":false},{"pmid":"30899831","id":"PMC_30899831","title":"Homology modeling and docking analysis of ßC1 protein encoded by Cotton leaf curl Multan betasatellite with different plant flavonoids.","date":"2019","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/30899831","citation_count":3,"is_preprint":false},{"pmid":"40590574","id":"PMC_40590574","title":"Biallelic ELOVL1 Variants Are Linked to Hypomyelinating Leukodystrophy, Movement Disorder, and Ichthyosis.","date":"2025","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/40590574","citation_count":1,"is_preprint":false},{"pmid":"30543080","id":"PMC_30543080","title":"Development of Virus Resistance Transgenic Cotton Using Cotton Leaf Curl Virus Antisense ßC1 Gene.","date":"2019","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/30543080","citation_count":0,"is_preprint":false},{"pmid":"39243948","id":"PMC_39243948","title":"Delayed simvastatin treatment improves neurological recovery after cryogenic traumatic brain injury through downregulation of ELOVL1 by inhibiting mTOR signaling.","date":"2024","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/39243948","citation_count":0,"is_preprint":false},{"pmid":"41539567","id":"PMC_41539567","title":"Time-dependent changes in meibum lipid composition and progression of dry eye following disruption of the fatty acid elongase Elovl1.","date":"2026","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41539567","citation_count":0,"is_preprint":false},{"pmid":"40894896","id":"PMC_40894896","title":"Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/40894896","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.05.23.595617","title":"Enzymes enabling the biosynthesis of various C<sub>20</sub>polyunsaturated fatty acids in a sea urchin<i>Hemicentrotus pulcherrimus</i>","date":"2024-05-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.23.595617","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.13.653734","title":"Very long chain fatty acids drive 1-deoxy-Sphingolipid toxicity","date":"2025-05-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.13.653734","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.02.620823","title":"The coordination between CTCF, cohesin and TFs impacts nucleosome repositioning and chromatin insulation to define state specific 3D chromatin folding","date":"2024-11-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.02.620823","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19417,"output_tokens":3696,"usd":0.056846},"stage2":{"model":"claude-opus-4-6","input_tokens":7094,"output_tokens":2702,"usd":0.15453},"total_usd":0.211376,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"ELOVL1 exhibits high enzymatic activity toward saturated and monounsaturated C20- and C22-CoAs, catalyzing their elongation to C24-CoA, and is essential for the production of C24 sphingolipids; its activity is co-regulated with ceramide synthase CERS2 to coordinate C24-CoA production with utilization; knockdown of ELOVL1 reduces LYN kinase activity, confirming C24-sphingolipid importance in membrane microdomain function.\",\n      \"method\": \"In vitro elongase activity assay with all seven ELOVL family members; siRNA knockdown; LYN kinase activity measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro substrate specificity assay across all ELOVLs with functional knockdown validation, replicated in multiple contexts\",\n      \"pmids\": [\"20937905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ELOVL1 is the single elongase responsible for synthesizing both saturated VLCFA (C26:0) and monounsaturated VLCFA (C26:1) from C22 substrates; ELOVL1 knockdown reduces C22:0-to-C26:0 elongation and lowers C26:0 levels in X-ALD fibroblasts, demonstrating that elevated C26:0 in X-ALD results from increased substrate availability (cytosolic VLCFA-CoA) rather than increased ELOVL1 expression.\",\n      \"method\": \"Stable isotope elongation assay; siRNA knockdown of ELOVL1 in X-ALD fibroblasts; GC-MS fatty acid profiling\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal biochemical methods in patient-derived cells with functional rescue\",\n      \"pmids\": [\"20166112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Elovl1 knockout mice die shortly after birth due to epidermal barrier defects; in the epidermis, loss of Elovl1 reduces ceramides with ≥C26 fatty acids and increases ceramides with ≤C24 fatty acids, and reduces C24 sphingomyelin; CerS2 and CerS3, expressed in epidermal-layer-specific manner, regulate Elovl1 to produce acyl-CoAs of different chain lengths, establishing Elovl1 as a key determinant of epidermal ceramide chain length.\",\n      \"method\": \"Elovl1 knockout mouse generation; lipidomics of stratum corneum; ultrastructural analysis of lipid lamellae; immunofluorescence for CerS2/CerS3\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with defined lipid phenotype plus molecular characterization of CerS2/CerS3 interaction\",\n      \"pmids\": [\"23689133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Oleic and erucic acids (components of Lorenzo's oil) inhibit ELOVL1 in a mixed (non-competitive) inhibition kinetics manner; the 4:1 mixture (Lorenzo's oil composition) shows the most potent inhibitory activity and reduces saturated VLCFA-sphingomyelin levels in cells, suggesting ELOVL1 inhibition underlies Lorenzo's oil mechanism of action.\",\n      \"method\": \"ELOVL1 activity assay with kinetic analysis; cellular sphingomyelin profiling by LC-MS/MS\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic kinetics with cellular validation\",\n      \"pmids\": [\"24489110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CoA esters of bezafibrate and gemfibrozil specifically inhibit ELOVL1 enzymatic activity; kinetic characterization using microsomal fractions from ELOVL1-overexpressing HEK293 cells established that fibrates act as inhibitors of ELOVL1-mediated chain elongation.\",\n      \"method\": \"Microsomal elongation assay from ELOVL1-overexpressing HEK293 cells; inhibition kinetics with fibrate CoA esters; X-ALD fibroblast elongation assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme kinetics with defined inhibitor mechanism\",\n      \"pmids\": [\"25499606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A dominant de novo ELOVL1 mutation (p.S165F) abrogates ELOVL1 enzymatic activity, reduces ≥C24 ceramides and sphingomyelins in patient fibroblasts, and causes ichthyosis, hypomyelination, spastic paraplegia, and optic atrophy; loading fibroblasts with C22:0-VLCFAs increased C24:0-ceramides and sphingomyelins, and competitive inhibition between saturated and monounsaturated VLCFAs for ceramide and sphingomyelin synthesis was identified.\",\n      \"method\": \"Stable isotope-labelled [13C]malonyl-CoA elongation assay; LC-MS/MS ceramide/sphingomyelin quantification; patient fibroblast studies; VLCFA loading experiments\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct enzymatic assay with patient mutation, multiple orthogonal methods, confirmed by independent lab (PMID 29496980)\",\n      \"pmids\": [\"30487246\", \"29496980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Elovl1 gene disruption in mice shortens acyl chain lengths in cholesteryl esters and wax esters in meibum lipids, causing dry eye phenotypes (increased eye-blink frequency, elevated water evaporation from ocular surface); aged Elovl1 mutant mice develop corneal opacity, establishing ELOVL1 as the primary elongase for saturated VLC meibum fatty acids and as essential for tear film lipid barrier function.\",\n      \"method\": \"Tissue-specific Elovl1 knockout mice; meibum lipid profiling; eye-blink frequency measurement; corneal phenotype analysis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined lipid and functional phenotype, replicated in follow-up study (PMID 41539567)\",\n      \"pmids\": [\"29401594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Elovl1 mutant mice show markedly shortened acyl chain lengths of sphingolipids (galactosylceramides, sulfatides, sphingomyelins, ceramides) in the brain, reduced galactosylceramide levels, modest hypomyelination especially in large-diameter axons, and behavioral deficits including poorer motor coordination and reduced acoustic startle response.\",\n      \"method\": \"Elovl1 mutant mouse analysis; brain lipidomics; electron microscopy of corpus callosum; behavioral testing\",\n      \"journal\": \"FASEB bioAdvances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with lipidomic and ultrastructural characterization plus functional behavioral readout\",\n      \"pmids\": [\"32123819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Elovl1 encodes a ubiquitously expressed microsomal enzyme involved in very long-chain fatty acid and sphingolipid synthesis; the mouse Elovl1 gene consists of eight exons spanning 5.4 kb and is arranged in a tail-to-tail array with the cell cycle gene p55Cdc, with both genes co-expressed during proliferation-differentiation transitions.\",\n      \"method\": \"Genomic cloning; DNA sequencing; Northern blot mRNA analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genomic characterization and expression analysis, single study\",\n      \"pmids\": [\"11891222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In zebrafish, Elovl1 knockdown increases long-chain fatty acids (C14–C20) and causes lipid droplet accumulation in the swim bladder; Elovl1a and Elovl1b are required for swim bladder inflation and gene expression in swim bladder development, while Elovl1b is additionally required for kidney development and renal clearance.\",\n      \"method\": \"Morpholino knockdown of elovl1a/b in zebrafish; Oil-Red-O lipid staining; gene expression analysis; renal clearance assay\",\n      \"journal\": \"Organogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown with lipid quantification and organogenesis phenotype, zebrafish ortholog\",\n      \"pmids\": [\"27078170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A homozygous splice site mutation in ELOVL1 (c.376-2A>G) causes exon skipping, leading to loss of ELOVL1 function with autosomal recessive inheritance; LC-MS/MS analysis of patient stratum corneum showed significant shortening of fatty acid moieties and severe reduction in acylceramide levels.\",\n      \"method\": \"Whole exome sequencing; RNA splicing analysis; LC-MS/MS ceramide profiling of stratum corneum\",\n      \"journal\": \"Brain & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — molecular characterization of splice variant with biochemical confirmation in patient tissue\",\n      \"pmids\": [\"35379526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Elovl1 inactivation in CD8+ T cells leads to accumulation of saturated long-chain fatty acids, which destabilizes INSIG1, activates SREBP2, increases plasma membrane cholesterol, and strengthens T cell receptor signaling; Elovl1-deficient T cells also show increased mitochondrial fitness and fatty acid oxidation.\",\n      \"method\": \"CRISPR/Cas9 metabolic screen; single-cell RNA sequencing; adoptive T cell transfer in vivo; INSIG1/SREBP2 pathway analysis; metabolic profiling\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen with mechanistic pathway validation (INSIG1-SREBP2), multiple orthogonal methods\",\n      \"pmids\": [\"40065102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Simvastatin downregulates ELOVL1 expression in astrocytes by inhibiting mTOR signaling after traumatic brain injury; overexpression of ELOVL1 in astrocytes partially attenuates the neuroprotective benefits of simvastatin, establishing that astrocytic ELOVL1 mediates VLCFA-dependent neurotoxicity downstream of mTOR.\",\n      \"method\": \"In vivo cryogenic TBI mouse model; AAV-mediated astrocytic ELOVL1 overexpression; mTOR pathway inhibition; saturated VLCFA quantification in cortex\",\n      \"journal\": \"Brain research bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic overexpression with pharmacological intervention and defined pathway placement\",\n      \"pmids\": [\"39243948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CRISPRi screening identified ELOVL1 as a key mediator of 1-deoxy-sphingolipid (1-deoxySL) toxicity; pharmacological inhibition of ELOVL1 alleviated cellular, mitochondrial, and neuronal toxicity induced by 1-deoxySLs; mechanistic studies showed that 1-deoxyDHceramide conjugated to nervonic acid (m18:0/24:1, a product requiring ELOVL1 activity) is the principal toxic species, inducing apoptosis through mitochondrial permeability transition pore formation.\",\n      \"method\": \"CRISPRi screen; genetic knockdown; cytotoxicity assays; stable isotope-resolved lipidomics via LC-MS/MS; mPTP inhibition with cyclosporin A; BAX inhibition\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen with mechanistic validation, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.05.13.653734\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ELOVL1 is a microsomal fatty acid elongase that catalyzes the rate-limiting condensation step in very long-chain fatty acid (VLCFA) synthesis, acting preferentially on saturated and monounsaturated C20–C22-CoA substrates to produce C24–C26 VLCFAs; these products are essential for C24-sphingolipid and acylceramide synthesis (coordinated with CERS2/CERS3), epidermal permeability barrier formation, tear film lipid composition, and myelin sphingolipid integrity, while in CD8+ T cells ELOVL1 activity controls membrane cholesterol homeostasis via an INSIG1-SREBP2 axis, and its inhibition is pursued therapeutically in X-linked adrenoleukodystrophy to reduce pathological C26:0 accumulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ELOVL1 is a ubiquitously expressed microsomal fatty acid elongase that catalyzes the rate-limiting condensation step in very long-chain fatty acid (VLCFA) synthesis, preferentially elongating saturated and monounsaturated C20–C22-CoA substrates to C24–C26 products that serve as precursors for sphingolipids, acylceramides, and meibum wax esters [PMID:20937905, PMID:20166112]. Its activity is coordinated with ceramide synthases CERS2 and CERS3 to match acyl-CoA production with utilization, and is essential for epidermal permeability barrier formation, tear film lipid integrity, and myelin sphingolipid composition, as demonstrated by neonatal lethality from barrier failure in knockout mice and hypomyelination with behavioral deficits in mutant mice [PMID:23689133, PMID:29401594, PMID:32123819]. Dominant (p.S165F) and recessive loss-of-function mutations in human ELOVL1 cause ichthyosis, hypomyelination, and spastic paraplegia, with patient fibroblasts and stratum corneum showing severe reductions in ≥C24 ceramides and sphingomyelins [PMID:30487246, PMID:35379526]. In CD8+ T cells, ELOVL1 inactivation shifts fatty acid pools to destabilize INSIG1, activate SREBP2-dependent cholesterol biosynthesis, increase membrane cholesterol, and enhance T cell receptor signaling and antitumor function [PMID:40065102].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Initial genomic characterization established that Elovl1 encodes a ubiquitously expressed microsomal enzyme involved in VLCFA and sphingolipid synthesis, providing the gene identity needed for subsequent functional studies.\",\n      \"evidence\": \"Genomic cloning, sequencing, and Northern blot analysis in mouse\",\n      \"pmids\": [\"11891222\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single descriptive study without enzymatic characterization\", \"No substrate specificity determined\", \"No loss-of-function data\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Biochemical comparison of all seven ELOVL family members revealed that ELOVL1 is the primary elongase for saturated and monounsaturated C20–C22-CoAs to C24–C26, resolving which elongase produces the bulk of VLCFA for sphingolipid synthesis and establishing that elevated C26:0 in X-ALD reflects increased substrate availability rather than ELOVL1 overexpression.\",\n      \"evidence\": \"In vitro elongase activity assays across all ELOVLs; stable isotope elongation assays and siRNA knockdown in X-ALD patient fibroblasts; GC-MS profiling\",\n      \"pmids\": [\"20937905\", \"20166112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo genetic confirmation yet in mammals\", \"Regulation of ELOVL1 expression and activity incompletely defined\", \"Precise mechanism of ELOVL1–CERS2 co-regulation unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genetic knockout in mice demonstrated that Elovl1 is non-redundant and essential for epidermal barrier function: loss of Elovl1 shortened ceramide acyl chains below C26, disrupted lipid lamellae, and caused neonatal lethality, establishing the physiological requirement for ELOVL1 in skin.\",\n      \"evidence\": \"Elovl1 knockout mice; stratum corneum lipidomics; ultrastructural analysis; CerS2/CerS3 immunofluorescence\",\n      \"pmids\": [\"23689133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution to non-epidermal tissues not yet assessed in this model\", \"Whether CerS3 can partially compensate in specific skin layers unclear\", \"No human genetic confirmation at this time\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Pharmacological studies showed that Lorenzo's oil fatty acids and fibrate-CoA esters inhibit ELOVL1 via mixed inhibition kinetics, identifying ELOVL1 as a druggable target for reducing pathological VLCFA accumulation.\",\n      \"evidence\": \"Microsomal ELOVL1 activity assays with kinetic analysis; LC-MS/MS cellular sphingomyelin profiling; inhibition studies in X-ALD fibroblasts\",\n      \"pmids\": [\"24489110\", \"25499606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of ELOVL1 inhibition for X-ALD not demonstrated\", \"No selective small-molecule ELOVL1 inhibitor developed\", \"Structural basis for inhibitor binding unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A dominant de novo ELOVL1 mutation (p.S165F) was shown to abolish enzymatic activity and cause ichthyosis, hypomyelination, spastic paraplegia, and optic atrophy in humans, while tissue-specific knockout in mice revealed ELOVL1's essential role in meibum VLCFA synthesis and tear film integrity, together extending the phenotypic spectrum from skin to brain and eye.\",\n      \"evidence\": \"Patient fibroblast isotope-labelled elongation assays and LC-MS/MS; tissue-specific Elovl1 knockout mice with meibum lipidomics and ocular phenotyping\",\n      \"pmids\": [\"30487246\", \"29496980\", \"29401594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype–phenotype correlations across multiple mutations not established\", \"Whether dominant-negative vs. haploinsufficiency mechanism applies unclear\", \"No therapeutic rescue in human disease attempted\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Brain-focused analysis of Elovl1 mutant mice revealed shortened sphingolipid acyl chains, reduced galactosylceramide, modest hypomyelination of large-diameter axons, and behavioral deficits, establishing ELOVL1's specific contribution to CNS myelin lipid composition.\",\n      \"evidence\": \"Brain lipidomics; corpus callosum electron microscopy; motor coordination and acoustic startle behavioral testing in Elovl1 mutant mice\",\n      \"pmids\": [\"32123819\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degree to which other elongases compensate in brain not quantified\", \"Impact on peripheral nervous system myelin not assessed\", \"Mechanism linking shortened acyl chains to hypomyelination not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of a homozygous splice site mutation confirmed autosomal recessive ELOVL1 deficiency as a human disease with severe acylceramide loss in stratum corneum, complementing the earlier dominant mutation and broadening the genetic landscape.\",\n      \"evidence\": \"Whole exome sequencing; RNA splicing analysis; LC-MS/MS ceramide profiling of patient stratum corneum\",\n      \"pmids\": [\"35379526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single family reported\", \"Functional rescue not performed\", \"CNS phenotype characterization limited\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Simvastatin was shown to downregulate ELOVL1 expression in astrocytes via mTOR inhibition, and astrocytic ELOVL1 overexpression partially reversed neuroprotection, placing ELOVL1 as a mediator of VLCFA-dependent neurotoxicity downstream of mTOR signaling after traumatic brain injury.\",\n      \"evidence\": \"Cryogenic TBI mouse model; AAV-mediated astrocytic ELOVL1 overexpression; mTOR pathway analysis; cortical VLCFA quantification\",\n      \"pmids\": [\"39243948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between specific VLCFA species and neurotoxicity not fully resolved\", \"Single pharmacological agent used to define pathway\", \"Not confirmed in human astrocytes\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A CRISPR metabolic screen in CD8+ T cells uncovered a non-canonical role for ELOVL1: its loss shifts fatty acid composition to destabilize INSIG1, activate SREBP2-mediated cholesterol synthesis, increase plasma membrane cholesterol, and amplify TCR signaling, enhancing antitumor T cell function in vivo.\",\n      \"evidence\": \"Genome-wide CRISPR/Cas9 screen; single-cell RNA-seq; adoptive T cell transfer; INSIG1/SREBP2 pathway analysis; metabolic profiling\",\n      \"pmids\": [\"40065102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ELOVL1 substrate(s) responsible for INSIG1 destabilization not identified at lipid species level\", \"Impact on other immune cell types unknown\", \"Therapeutic window for T cell-directed ELOVL1 inhibition not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for ELOVL1 substrate selectivity and inhibitor binding, the development of selective ELOVL1 inhibitors suitable for clinical use, the full genotype–phenotype spectrum of ELOVL1 deficiency in humans, and the molecular mechanism linking shortened acyl-chain sphingolipids to hypomyelination.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of ELOVL1\", \"No selective small-molecule inhibitor advanced to preclinical studies\", \"Mechanism by which C24-sphingolipid loss causes myelin instability not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5, 6, 7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CERS2\",\n      \"CERS3\",\n      \"INSIG1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}